Diana Lüftner1, Andreas D Hartkopf2, Michael P Lux3,4, Friedrich Overkamp5, Hans Tesch6, Adriana Titzmann7, Patrik Pöschke7, Markus Wallwiener8, Volkmar Müller9, Matthias W Beckmann7, Erik Belleville10, Wolfgang Janni11, Tanja N Fehm12, Hans-Christian Kolberg13, Johannes Ettl14, Diethelm Wallwiener2, Andreas Schneeweiss15, Sara Y Brucker2, Peter A Fasching7. 1. Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany. 2. Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany. 3. Department of Gynecology and Obstetrics, Frauenklinik St. Louise Paderborn, St. Josefs-Krankenhaus, Salzkotten, Germany. 4. Kooperatives Brustzentrum Paderborn, Paderborn, Germany. 5. OncoConsult Overkamp GmbH, Berlin, Germany. 6. Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany. 7. Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany. 8. Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany. 9. Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany. 10. ClinSol GmbH and Co. KG, Würzburg, Germany. 11. Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany. 12. Department of Gynecology and Obstetrics, Düsseldorf University Hospital, Düsseldorf, Germany. 13. Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany. 14. Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany. 15. National Center for Tumor Diseases and Department of Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, Germany.
Abstract
BACKGROUND: The therapeutic armamentarium for patients with metastatic breast cancer is becoming more and more specific. Recommendations from clinical trials are not available for all treatment situations and patient subgroups, and it is therefore important to collect real-world data. SUMMARY: To develop recommendations for up-to-date treatments and participation in clinical trials for patients with metastatic breast cancer, the Prospective Academic Translational Research PRAEGNANT Network was established to optimize the quality of oncological care in the advanced therapeutic setting. The main aim of PRAEGNANT is to systematically record medical care for patients with metastatic breast cancer in the real-life setting, including the outcome and side effects of different treatment strategies, to monitor quality-of-life changes during therapy, to identify patients eligible for participation in clinical studies, and to allow targeted therapies based on the molecular structures of breast carcinomas. KEY MESSAGES: This article describes the PRAEGNANT network and sheds light on the question of whether the various end points from clinical trials can be transferred to the real-world treatment situation.
BACKGROUND: The therapeutic armamentarium for patients with metastatic breast cancer is becoming more and more specific. Recommendations from clinical trials are not available for all treatment situations and patient subgroups, and it is therefore important to collect real-world data. SUMMARY: To develop recommendations for up-to-date treatments and participation in clinical trials for patients with metastatic breast cancer, the Prospective Academic Translational Research PRAEGNANT Network was established to optimize the quality of oncological care in the advanced therapeutic setting. The main aim of PRAEGNANT is to systematically record medical care for patients with metastatic breast cancer in the real-life setting, including the outcome and side effects of different treatment strategies, to monitor quality-of-life changes during therapy, to identify patients eligible for participation in clinical studies, and to allow targeted therapies based on the molecular structures of breast carcinomas. KEY MESSAGES: This article describes the PRAEGNANT network and sheds light on the question of whether the various end points from clinical trials can be transferred to the real-world treatment situation.
Authors: Jennifer K Litton; Hope S Rugo; Johannes Ettl; Sara A Hurvitz; Anthony Gonçalves; Kyung-Hun Lee; Louis Fehrenbacher; Rinat Yerushalmi; Lida A Mina; Miguel Martin; Henri Roché; Young-Hyuck Im; Ruben G W Quek; Denka Markova; Iulia C Tudor; Alison L Hannah; Wolfgang Eiermann; Joanne L Blum Journal: N Engl J Med Date: 2018-08-15 Impact factor: 91.245
Authors: Markus Wallwiener; Felix Heindl; Sara Y Brucker; Florin-Andrei Taran; Andreas Hartkopf; Friedrich Overkamp; Hans-Christian Kolberg; Peyman Hadji; Hans Tesch; Johannes Ettl; Michael P Lux; Claudia Rauh; Simon Blum; Naiba Nabieva; Tobias F Brodkorb; Cornelia Faschingbauer; Hanna Langemann; Carla Schulmeyer; Bernhard Volz; Matthias Rübner; Diana Lüftner; Volkmar Müller; Erik Belleville; Wolfgang Janni; Tanja N Fehm; Diethelm Wallwiener; Thomas Ganslandt; Matthias W Beckmann; Andreas Schneeweiss; Peter A Fasching; Paul Gass Journal: Geburtshilfe Frauenheilkd Date: 2017-08-24 Impact factor: 2.915
Authors: Alexander Hein; Paul Gass; Christina Barbara Walter; Florin-Andrei Taran; Andreas Hartkopf; Friedrich Overkamp; Hans-Christian Kolberg; Peyman Hadji; Hans Tesch; Johannes Ettl; Rachel Wuerstlein; Debra Lounsbury; Michael P Lux; Diana Lüftner; Markus Wallwiener; Volkmar Müller; Erik Belleville; Wolfgang Janni; Tanja N Fehm; Diethelm Wallwiener; Thomas Ganslandt; Matthias Ruebner; Matthias W Beckmann; Andreas Schneeweiss; Peter A Fasching; Sara Y Brucker Journal: Breast Cancer Res Treat Date: 2016-06-09 Impact factor: 4.872
Authors: Andreas D Hartkopf; Jens Huober; Bernhard Volz; Naiba Nabieva; Florin-Andrei Taran; Judith Schwitulla; Friedrich Overkamp; Hans-Christian Kolberg; Peyman Hadji; Hans Tesch; Lothar Häberle; Johannes Ettl; Michael P Lux; Diana Lüftner; Markus Wallwiener; Volkmar Müller; Matthias W Beckmann; Erik Belleville; Pauline Wimberger; Carsten Hielscher; Matthias Geberth; Nikos Fersis; Wolfgang Abenhardt; Christian Kurbacher; Rachel Wuerstlein; Christoph Thomssen; Michael Untch; Peter A Fasching; Wolfgang Janni; Tanja N Fehm; Diethelm Wallwiener; Sara Y Brucker; Andreas Schneeweiss Journal: Breast Date: 2017-10-26 Impact factor: 4.380